Lara Traeger
Associate Professor
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (2)
UNSTRUCTURED South Africa (SA) has the largest HIV epidemic in the world; in KwaZulu-Natal (KZN) Province, over 40.8% of adults over 15 are living with HIV. Despite this, SA is home to only 3% of the world’s healthcare workers. Nurses constitute the largest group of providers in SA and experience high levels of burnout, which can contribute to negative patient outcomes for persons living with HIV (PWH), including reduced treatment adherence. Patient-provider relationships are the gateway to engagement and retention in HIV care yet relationships can be compromised in overburdened nurses. Nurse-centered interventions that offset these effects are urgently needed. The purpose of this study is to pilot an adapted resiliency-based mind-body intervention (the Relaxation Response Resiliency Program; the 3RP) for nurses that provide care for PWH in the public sector in SA. In Phase 1 [NIH Grant Number: R34MH131426; HREC Ethics Reference Number: 220813], we conducted focus group discussions to solicit feedback on: the role of culture and perceptions of stress; the lived experiences of stress; sources of stress (e.g., occupational, trauma-related); how stress impacts job functioning (specifically patient care); current coping strategies; and the proposed intervention modules (content, number of sessions, session duration, program length, use of coaches, mode of delivery (e.g., virtual, in-person, hybrid approaches), etc.). In this Phase 2, we will conduct a small proof-of-concept study (N = 8-10), followed by a randomized pilot (N = 60), of nurses that care for PWH in the public sector in SA to test the feasibility and acceptability of the adapted intervention.
Year:
2025
PURPOSE Immunotherapy has improved survival for patients with melanoma and non–small cell lung cancer (NSCLC). Yet, as responses vary widely, immunotherapy also introduces challenges in prognostic communication. In this study, we sought to explore how patients and caregivers learned about the goal of immunotherapy and their experience of living with uncertainty. MATERIALS AND METHODS We conducted a qualitative study of patients with stage III or IV melanoma or stage IV NSCLC within 12 weeks of initiating or 12 months of discontinuing immunotherapy, and their caregivers. We conducted in-depth interviews with participants to explore how they learned about immunotherapy from oncology clinicians and how they experienced uncertainty. We used a framework approach to analyze interview transcripts and synthesized concepts into themes. RESULTS Forty-two patients and 10 caregivers participated; median age was 67 years and most were male (68%), white (95%), married (61%), and had melanoma (62%). We identified four themes: (1) the oncology team shaped participants' hopeful expectations of immunotherapy, including as a potential cure among those with melanoma; (2) distress related to prognostic uncertainty particularly affected patients who experienced toxicity or progressive disease; (3) patients who did not have long-term responses experienced overwhelming disappointment; and (4) some patients and caregivers had conflicting preferences for prognostic information. Participants provided suggestions to improve education and underscored unmet psychosocial needs. CONCLUSION Patients and caregivers held optimistic expectations of immunotherapy, which resulted in heightened disappointment among the subset with progression or toxicity. Clinicians should elicit information preferences of both patients and caregivers, as these may be disparate. Our results highlight the need to optimize prognostic communication and support for living with uncertainty among patients receiving immunotherapy.
Year:
2025
Collaborators (4)
Elyse Park
Harvard University
Amelia Stanton
Boston University
Ryan Sullivan
Harvard University
Jennifer Temel
Massachusetts General Hospital
Make your next move.
Prepare your application
Review drafts before you send them.